Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Sunesis Offers Updates on SNS-062 and Qinprezo Programs
by Zacks Equity Research
Sunesis (SNSS) provided updates on two of its lead programs: SNS-062, and Qinprezo (vosaroxin).
Can AbbVie (ABBV) Spring a Surprise This Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.
Q4 Earnings Roundup: JNJ, VZ, MMM, DD, Etc.
by Mark Vickery
Ahead of the opening bell today, we have plenty of Q4 earnings results to report.
J&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) reported a mixed quarter with earnings beating expectations while sales missing the same.
The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies
J&J (JNJ) Beats on Q4 Earnings, Sales Miss; Stock Down
by Zacks Equity Research
JNJ beat on fourth quarter earnings - the company reported EPS of $1.58 while our consensus called for EPS of $1.56.
The Best Earnings Charts on the Street
by Tracey Ryniec
It's not easy to beat on earnings every quarter for years but these companies are doing it.
Dow Stocks to Watch for Earnings on Nov 24: DD, JNJ, TRV, VZ
by Swarup Gupta
The nature of these releases is likely to determine the fortunes of the Dow in the days ahead.
Can Q4 Earnings Revitalize Healthcare ETFs?
by Sweta Killa
The Q4 earnings could bring some near-term relief given that the sector is expected to post earnings growth of 2.9% and revenue growth of 5.6%.
5 Best Performing Healthcare Mutual Funds of 2016
by Zacks Equity Research
Investors rely on the healthcare firms to safeguard their investments as demand for its services does not vary much with market conditions
J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio
by Zacks Equity Research
Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ), announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company.
What's in Store for Abbott Labs (ABT) This Earnings Season?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.
Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
by Zacks Equity Research
Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
by Madeleine Johnson
After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.
Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.
5 ETF Investment Ideas for 2017
by Neena Mishra
We have highlighted some ETF areas that are likely to shine in 2017.
Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study
by Zacks Equity Research
Bristol-Myers (BMY) and GeneCentric Diagnostics inked an exploratory biomarker research collaboration.
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)
by Zacks Equity Research
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study
by Zacks Equity Research
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
by Zacks Equity Research
Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.
Lilly Jardiance Family Diabetes Drugs' Label to be Updated
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.
Company News for January 03, 2017
by Zacks Equity Research
Companies In The News are: MYL,JNJ,GPOR,PBR,S,TMUS
Mylan (MYL) Announces Multiple Generic Launches in the U.S.
by Zacks Equity Research
Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.